vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $192.4M, roughly 1.5× Xometry, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -4.5%, a 100.8% gap on every dollar of revenue. On growth, Xometry, Inc. posted the faster year-over-year revenue change (29.5% vs 9.4%). Over the past eight quarters, Xometry, Inc.'s revenue compounded faster (25.2% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
ACAD vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $192.4M |
| Net Profit | $273.6M | $-8.6M |
| Gross Margin | 90.8% | 39.1% |
| Operating Margin | 6.1% | -4.6% |
| Net Margin | 96.3% | -4.5% |
| Revenue YoY | 9.4% | 29.5% |
| Net Profit YoY | 90.3% | 12.7% |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $192.4M | ||
| Q3 25 | $278.6M | $180.7M | ||
| Q2 25 | $264.6M | $162.5M | ||
| Q1 25 | $244.3M | $151.0M | ||
| Q4 24 | $259.6M | $148.5M | ||
| Q3 24 | $250.4M | $141.7M | ||
| Q2 24 | $242.0M | $132.6M | ||
| Q1 24 | $205.8M | $122.7M |
| Q4 25 | $273.6M | $-8.6M | ||
| Q3 25 | $71.8M | $-11.6M | ||
| Q2 25 | $26.7M | $-26.4M | ||
| Q1 25 | $19.0M | $-15.1M | ||
| Q4 24 | $143.7M | $-9.9M | ||
| Q3 24 | $32.8M | $-10.2M | ||
| Q2 24 | $33.4M | $-13.7M | ||
| Q1 24 | $16.6M | $-16.6M |
| Q4 25 | 90.8% | 39.1% | ||
| Q3 25 | 92.2% | 39.9% | ||
| Q2 25 | 92.2% | 40.1% | ||
| Q1 25 | 91.7% | 37.3% | ||
| Q4 24 | 91.6% | 39.7% | ||
| Q3 24 | 92.5% | 39.4% | ||
| Q2 24 | 92.5% | 39.9% | ||
| Q1 24 | 88.8% | 39.0% |
| Q4 25 | 6.1% | -4.6% | ||
| Q3 25 | 12.8% | -6.1% | ||
| Q2 25 | 12.2% | -6.3% | ||
| Q1 25 | 7.9% | -10.2% | ||
| Q4 24 | 59.1% | -7.8% | ||
| Q3 24 | 12.6% | -8.1% | ||
| Q2 24 | 12.6% | -11.5% | ||
| Q1 24 | 7.4% | -14.6% |
| Q4 25 | 96.3% | -4.5% | ||
| Q3 25 | 25.8% | -6.4% | ||
| Q2 25 | 10.1% | -16.3% | ||
| Q1 25 | 7.8% | -10.0% | ||
| Q4 24 | 55.4% | -6.7% | ||
| Q3 24 | 13.1% | -7.2% | ||
| Q2 24 | 13.8% | -10.3% | ||
| Q1 24 | 8.0% | -13.5% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $275.6M |
| Total Assets | $1.6B | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $219.1M | ||
| Q3 25 | $258.0M | $224.5M | ||
| Q2 25 | $253.6M | $225.8M | ||
| Q1 25 | $217.7M | $231.4M | ||
| Q4 24 | $319.6M | $239.8M | ||
| Q3 24 | $155.1M | $234.0M | ||
| Q2 24 | $177.1M | $240.9M | ||
| Q1 24 | $204.7M | $253.8M |
| Q4 25 | $1.2B | $275.6M | ||
| Q3 25 | $917.3M | $272.0M | ||
| Q2 25 | $822.4M | $270.4M | ||
| Q1 25 | $765.2M | $309.9M | ||
| Q4 24 | $732.8M | $314.5M | ||
| Q3 24 | $577.2M | $315.2M | ||
| Q2 24 | $516.7M | $315.8M | ||
| Q1 24 | $464.0M | $320.4M |
| Q4 25 | $1.6B | $703.7M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.2B | $687.0M | ||
| Q1 25 | $1.1B | $690.1M | ||
| Q4 24 | $1.2B | $680.1M | ||
| Q3 24 | $976.9M | $678.2M | ||
| Q2 24 | $914.1M | $678.6M | ||
| Q1 24 | $855.1M | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $4.4M |
| Free Cash FlowOCF − Capex | — | $-5.9M |
| FCF MarginFCF / Revenue | — | -3.0% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $4.4M | ||
| Q3 25 | $74.3M | $5.8M | ||
| Q2 25 | $64.0M | $-427.0K | ||
| Q1 25 | $20.3M | $-3.7M | ||
| Q4 24 | $40.4M | $9.1M | ||
| Q3 24 | $63.2M | $-3.6M | ||
| Q2 24 | $25.0M | $-9.1M | ||
| Q1 24 | $29.1M | $-11.7M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | $73.9M | $-1.7M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-9.2M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $63.2M | $-8.4M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-16.1M |
| Q4 25 | — | -3.0% | ||
| Q3 25 | 26.5% | -0.9% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | 25.2% | -6.0% | ||
| Q2 24 | — | -10.2% | ||
| Q1 24 | — | -13.1% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | 0.1% | 4.1% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | 0.0% | 3.4% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
